0000914475-15-000004.txt : 20150106 0000914475-15-000004.hdr.sgml : 20150106 20150106171756 ACCESSION NUMBER: 0000914475-15-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150105 FILED AS OF DATE: 20150106 DATE AS OF CHANGE: 20150106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Grigoriadis Dimitri E. CENTRAL INDEX KEY: 0001423838 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 15511038 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-01-05 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001423838 Grigoriadis Dimitri E. NEUROCRINE BIOSCIENCES, INC. 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Research Officer Common Stock 2015-01-05 4 M 0 2500 5.12 A 79558 D Common Stock 2015-01-05 4 S 0 2500 22.76 D 77058 D Incentive Stock Option 5.12 2015-01-05 4 M 0 2500 5.12 D 2015-02-27 Common Stock 2500 0 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.52 to $22.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option was granted February 27, 2008 and vested in 36 equal monthly installments beginning March 27, 2008. Timothy P. Coughlin, By Power of Attorney 2015-01-06 EX-24 2 grigoriadispoa.htm LIMITED POWER OF ATTORNEY

LIMITED POWER OF ATTORNEY - SECURITIES LAW COMPLIANCE





 The undersigned, as an Officer of Neurocrine Biosciences, Inc. (the "Corporation"),

hereby constitutes and appoints, jointly and severally Kevin C. Gorman, Timothy P. Coughlin

and Darin Lippoldt, each of them, the undersigned's true and lawful attorney-in-fact and agent,

each with the power of substitution for her in any and all capacities to complete and execute such

Forms 144, advisable pursuant to Rule 144 promulgated under the Securities Act of 1933 (as

amended) and Forms 3, 4, and 5 advisable pursuant to section 16 of the Securities Exchange Act

of 1934, and other forms as such attorney shall in his or her discretion determine to be required

by the rules and regulations promulgated thereunder, or any successor laws and regulations, as a

consequence of the undersigned's ownership, acquisition or disposition of securities of the

Corporation, and to do all acts necessary in order to file such forms with the Securities and

Exchange Commission, any securities exchange or national association, the Corporation and

such other person or agency as the attorney shall deem appropriate.  The undersigned hereby

ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by

virtue hereof.



 This Limited Power of Attorney is executed at San Diego, California, as of the date set

forth below.





       __________________________________

       (Signature) Dimitri E. Grigoriadis



      Date:  1/6/15